Akari Therapeutics (NASDAQ:AKTX) Share Price Passes Above 50-Day Moving Average of $1.97

Akari Therapeutics, Plc (NASDAQ:AKTX) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.97 and traded as high as $3.11. Akari Therapeutics shares last traded at $2.72, with a volume of 20,302 shares traded.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Akari Therapeutics in a report on Thursday. They issued a “sell” rating for the company.

Akari Therapeutics Stock Up 6.1 %

The business has a 50 day simple moving average of $2.04 and a 200-day simple moving average of $2.22.

Institutional Investors Weigh In On Akari Therapeutics

A hedge fund recently raised its stake in Akari Therapeutics stock. Omnia Family Wealth LLC raised its stake in Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 87,628 shares of the biopharmaceutical company’s stock after purchasing an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned about 1.55% of Akari Therapeutics worth $273,000 at the end of the most recent quarter. 5.06% of the stock is owned by institutional investors and hedge funds.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.